⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
SAILIFE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.5
| Stock Code | SAILIFE | Market Cap | 21,498 Cr. | Current Price | 1,014 ₹ | High / Low | 1,084 ₹ |
| Stock P/E | 64.2 | Book Value | 109 ₹ | Dividend Yield | 0.00 % | ROCE | 14.1 % |
| ROE | 11.0 % | Face Value | 1.00 ₹ | DMA 50 | 941 ₹ | DMA 200 | 873 ₹ |
| Chg in FII Hold | -1.09 % | Chg in DII Hold | 1.49 % | PAT Qtr | 104 Cr. | PAT Prev Qtr | 83.0 Cr. |
| RSI | 58.2 | MACD | 23.3 | Volume | 6,07,031 | Avg Vol 1Wk | 6,37,916 |
| Low price | 635 ₹ | High price | 1,084 ₹ | PEG Ratio | 0.27 | Debt to equity | 0.15 |
| 52w Index | 84.4 % | Qtr Profit Var | 103 % | EPS | 15.7 ₹ | Industry PE | 27.6 |
📊 Financial Overview
- Revenue & Profit Growth: Quarterly PAT rose from ₹83 Cr. to ₹104 Cr. (103% growth).
- Margins: ROE at 11.0% and ROCE at 14.1% → moderate efficiency.
- Debt: Debt-to-equity ratio of 0.15 → low leverage, healthy balance sheet.
- Cash Flow: Stable, supported by improving profitability.
- Return Metrics: EPS at ₹15.7, showing earnings growth momentum.
💹 Valuation Indicators
- P/E Ratio: 64.2 vs Industry PE of 27.6 → significantly overvalued.
- P/B Ratio: Price ₹1,014 / Book Value ₹109 ≈ 9.3.
- PEG Ratio: 0.27 → suggests valuation is expensive relative to growth.
- Intrinsic Value: Current valuation stretched, limited margin of safety.
🏢 Business Model & Competitive Advantage
- Operates in life sciences and pharma services, focusing on research-driven growth.
- Strong competitive advantage through niche expertise and innovation.
- Low debt enhances financial stability.
- Challenges include high valuation and reliance on consistent R&D outcomes.
📈 Entry Zone Recommendation
- Technicals: RSI at 58.2 (neutral to slightly overbought), MACD positive, price above 50DMA (941) and 200DMA (873).
- Entry Zone: Attractive accumulation near ₹950–980 for long-term investors.
- Holding Guidance: Suitable for long-term holding given strong growth potential, but valuations remain stretched.
✅ Positive
- Quarterly PAT growth of 103% shows strong momentum.
- Low debt-to-equity ratio (0.15).
- DII holdings increased (+1.49%).
⚠️ Limitation
- High P/E (64.2) compared to industry average (27.6).
- High P/B ratio (9.3).
- No dividend yield (0.00%).
📉 Company Negative News
- FII holdings decreased (-1.09%).
- Stock corrected from ₹1,084 to ₹1,014.
📈 Company Positive News
- Quarterly PAT surged to ₹104 Cr.
- DII confidence increased (+1.49%).
- Strong technical momentum with MACD positive.
🌐 Industry
- Life sciences and pharma services industry has strong long-term demand drivers.
- Industry PE at 27.6 indicates sector trades at lower valuations compared to SAILIFE.
- Global demand for innovation-driven pharma supports growth potential.
🔎 Conclusion
- SAILIFE shows strong profit growth and financial stability with low debt.
- Valuations are stretched, limiting near-term upside.
- Best considered as a long-term hold with entry near ₹950–980 for margin of safety.